Efficacy of antiviral drug combinations against equine herpes virus type 1 in vitro
MetadataShow full item record
Type of Workapplication/pdf
vii, 66 pages
DepartmentTowson University. Department of Biological Sciences
RightsCopyright protected, all rights reserved.
There are no restrictions on access to this document. An internet release form signed by the author to display this document online is on file with Towson University Special Collections and Archives.
Equine herpes virus type-1 (EHV-1) is responsible for a neurological infection in horses called equine herpes myeloencephalopathy (EHM). There is currently no specific treatment or vaccine licensed against the neuropathogenic EHV-1 strain (T953). In this study, the effect of combining the antiviral drugs cidofovir, foscarnet, and acyclovir was investigated. Specifically, we looked at the effect of using cidofovir + foscarnet and cidofovir + acyclovir against neuropathogenic EHV-1 (T953) propagated in equine dermal fibroblast (E. Derm) cells. This is the first study to look at the effect of combining different antiviral drugs against EHV-1 (T953). The combination of cidofovir (4 u/mL) + acyclovir (10 ?/mL) and cidofovir (7.5 ?/mL) + foscarnet (5 u/mL) were found to be non-toxic and to have an additive and no effect against EHV-1 (T953), respectively. These drug concentrations were also found to be non-toxic to E. Derm cells.